Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. 1986

J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle

Stored blood samples from 164 intravenous drug abusers who attended a Scottish general practice were tested for HTLV-III/LAV (human T cell lymphotropic virus type III/lymphadenopathy associated virus) infection. Of those tested, 83 (51%) were seropositive, which is well above the prevalence reported elsewhere in Britain and Europe and approaches that observed in New York City. The timing of taking samples of negative sera and continued drug use suggest that as many as 85% of this population might now be infected. The infection became epidemic in late 1983 and early 1984, thereafter becoming endemic. The practice of sharing needles and syringes correlated with seropositivity, which, combined with the almost exclusive intravenous use of heroin and other behavioural patterns, may explain the high prevalence of HTLV-III/LAV infection in the area. Rapid and aggressive intervention is needed to control the spread of infection.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
May 1986, British medical journal (Clinical research ed.),
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
June 1986, British medical journal (Clinical research ed.),
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
July 1986, Quintessenz Journal,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
January 1986, Pennsylvania medicine,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
January 1986, AIDS research,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
January 1986, Pathologica,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
January 1986, NIDA research monograph,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
October 1992, International journal of epidemiology,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
January 1986, International review of experimental pathology,
J R Robertson, and A B Bucknall, and P D Welsby, and J J Roberts, and J M Inglis, and J F Peutherer, and R P Brettle
August 1985, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!